Will Innovation Replace Branded Generics As Dominant Strategy For Big Pharma In Emerging Markets?
This article was originally published in The Pink Sheet Daily
Pricing pressure will increase over time in emerging markets, hitting the bottom line of multinationals, particularly those with high exposure to branded generics, Deutsche Bank predicts.
You may also be interested in...
Sanofi-Aventis Emerging Markets Sales Exceed U.S., Europe: Emerging Markets Earnings Round Up (Part 2)
Year-end and Q4 pharma earnings results emphasized emerging markets as one positive in a challenging environment posed by U.S. healthcare reform and European price cuts and austerity measures. Pharma companies stressed cost-cutting actions such as restructuring their businesses and closing facilities in the U.S. and Europe, while simultaneously discussing increased resource allocation for Asia and other emerging markets.
SHANGHAI - As China gets closer to completing its initial $124 billion healthcare reforms next year, analysts are expecting a strong surge in volume-driven growth backed by more provincial drug reimbursement. A top priority of the Chinese reforms is to extend healthcare insurance to 90 percent (1.3 billion) of China's population by the end of 2011, a goal most expect the government to reach
Russia has called for half of all pharmaceuticals in the country to be produced domestically in the next decade, pledging to spend 122.9 billion rubles ($3.97 billion) to get international drug makers to shift drug production to the country and strengthen R&D collaboration